New therapies for castrate-resistant prostate cancer

By Williams Stephen B   Lay Aaron H   Lau Clayton S   Josephson David Y   Wilson Timothy G   Choueiri Toni K   Pal Sumanta K  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2069-2074

Informa Healthcare

Access to resources Recommend Favorite

Castrate-resistant prostate cancer: therapeutic strategies

By Harzstark Andrea L   Small Eric J  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 937-945

Informa Healthcare

Access to resources Recommend Favorite

Zibotentan for the treatment of castrate-resistant prostate cancer

By Shepard Dale R   Dreicer Robert  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 899-908

Informa Healthcare

Access to resources Recommend Favorite

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α_v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

By Chu Franklin   Picus Joel   Fracasso Paula   Dreicer Robert   Lang Zhihui   Foster Brenda  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 674-679

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite